

To
The General Manager
BSE Limited
Corporate Relation Department
Phiroze Jeejeeboy Towers, 14th Floor,
Dalal Street, Fort, Mumbai- 400 001
Scrip Code: 524731

Dear Sir/Ma'am,

Reg.: 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.

Sub: Intimation of closure of buyback of equity shares by Jenburkt Pharmaceuticals Limited through open market in terms of the provisions of the Companies Act, 2013 and its rules, as amended and SEBI (Buy-back of Securities) Regulations, 2018, as amended (“Buyback Regulations”)

This is in furtherance to, (i) our intimation letter No.:JPL/CS/1832/2022 dated November 28, 2022, regarding convening of meeting of the board of directors of the Company ("**Board**") to approve the Buyback (as defined hereinafter), (ii) our letter No. JPL/CS/1835/2022 dated December 1, 2022, informing the outcome of the meeting of the Board where the buyback of our equity shares via the "Open Market" route through the stock exchanges mechanism was approved (iii) our letter No. JPL/CS/1839/2022 dated 05th December, 2022, regarding the submission of public announcement dated 03rd December, 2022 ("Public Announcement") and (iv) our intimation letter No. JPL/CS/1942/2023 dated 21st March, 2023, regarding convening of meeting of the buyback committee of the Company, to approve closure of the Buyback (as defined hereinafter).

Pursuant to the resolutions passed by the Board at its meeting held on 01st December , 2022, the Company was authorized to buyback its fully paid-up equity shares of face value of Rs. 10/- (Rupees Ten only) each ("**Equity Shares**") at a price not exceeding Rs. 702/- (Rupees Seven Hundred and Two only) per Equity Share (the "**Maximum Buyback Price**") payable in cash for an aggregate amount not exceeding Rs. 11,60,00,000/- (Rupees Eleven Crores Sixty Lakhs only) (the "**Maximum Buy-back Size**"), Company was also authorised to utilize at least 50% of the Maximum Buyback Size i.e. Rs. 5,80,00,000/- (Rupees Five Crore Eighty Lakhs Only) ("**Minimum Buyback Size**") towards the Buyback of equity shares in terms of the Buyback regulations, from the shareholders of the Company excluding promoters, promoter group and persons who are in control of the Company, via the "Open Market" route through the stock exchange mechanism, i.e., using the electronic trading facilities of the stock exchange where the Equity Shares of the Company are listed (i.e., **BSE Limited**), in accordance with the provisions of the Buyback Regulations and the Companies Act, 2013 (including the rules and regulations framed thereunder), as amended, and other provisions of the applicable laws(the process herein referred to as the "**Buyback**").

The above stated Maximum or Minimum Buyback Size do not include any expenses incurred or to be incurred for the Buyback like filing fees payable to SEBI, advisors' fees, stock exchange fees, brokerage, costs, fees, turnover charges, applicable taxes including inter alia securities transaction tax, goods and services tax, stamp duty, etc., public announcement publication expenses and other incidental and related expenses and charges (collectively referred to as **“Transaction Costs”**).

The Buyback commenced on 13th December, 2022 on the trading platform of BSE Ltd., in accordance with the provisions of Buyback Regulations. In this regard, please be informed that the Company has as at 24th March, 2023 bought back 1,76,078 (One Lakh Seventy Six Thousand Seventy Eight) Equity Shares, in aggregate, at an average price of ₹ 648.80 (Rupees Six Hundred Forty Eight and Eighty Paise Only) per Equity Share for an aggregate consideration of ₹11,42,39,205.25 (Rupees Eleven Crore Forty Two Lakh Thirty Nine Thousand Two Hundred Five Rupees And Zero Paise Only) excluding Transaction Cost, which represents 98.48% of the Maximum Buyback Size. Accordingly, the Buyback Committee hereby approves the closure of Buyback pursuant to the terms of the Public Announcement, with effect from the closing of trading hours of 24th March, 2023, prior to the six months from the date of commencement of the Buyback.

The summary of the pre and post Buyback shareholding pattern of the Company is enclosed as **Annexure I**.

This is for your information and records and may be treated as compliance under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

All capitalised terms not defined herein shall have the same meaning, as specified in the Public Announcement.

A copy of this intimation is also being made available on the Company's website at www.jenburkt.com.

For Jenburkt Pharmaceuticals Limited,

Ashish R. Shah
Company Secretary and Compliance Officer.

Place: Mumbai,
Date: 24th March, 2023.

Annexure I

Shareholding pattern of the Company Pre Buyback and Post Buyback, is given below:

Category	Pre-Buyback*		Post Buyback [#]	
	No. of Equity Shares	%	No. of Equity Shares	%
(A) Promoter & Promoter Group	20,98,788	45.73	20,98,788	47.56
(B) Public	24,90,590	54.27	23,14,512	52.44
Total (A+B)	45,89,378	100.00	44,13,300	100.00

* As disclosed in the Public Announcement.

In terms of the Buyback Regulations, till 03rd March, 2023 the Company has already extinguished 1,53,411 (One Lacs Fifty Tree Thousand Four Hundred Eleven) Equity shares bought back. The Company shall extinguished the balance of 22,667 (Twenty Two Thousand Six Hundred Sixty Seven) Equity shares aggregating 1,76,078 (One Lakh Seventy Six Thousand Seventy Eight) Equity shares Bought back. The Post Buy-back equity Share Capital is assuming extinguishment of all equity shares bought back by the Company until closure of the Buy-back.

For Jenburkt Pharmaceuticals Limited,

Ashish R. Shah
Company Secretary and Compliance Officer.

Place: Mumbai,
Date: 24th March, 2023.